‏516.00 ₪

MAUDSLEY PRESCRIBING GUIDELINES 12E

‏516.00 ₪

ISBN13

9781118754603

יצא לאור ב

Hoboken

מהדורה

זמן אספקה

21 ימי עסקים

עמודים

760

פורמט

Paperback / softback

תאריך יציאה לאור

10 בינו׳ 2015

מחליף את פריט

14597948000

The fully updated 12th edition of an essential reference for anyone responsible for prescribing drugs for patients with mental health disorders.

לדלג לסוף של גלריית תמונות

לדלג להתחלה של גלריית תמונות

פרטים

The fully updated 12th edition of an essential reference for anyone responsible for prescribing drugs for patients with mental health disorders. A well-respected and widely-used source of information on which drugs to prescribe, which side effects to look out for, how best to augment or switch drugs, and more Provides concise reviews of psychiatric disorders and relevant psychopharmacology, along with general guidance based on the data reviewed and current clinical practice Includes specific guidance for schizophrenia, bipolar disorder, depression, anxiety, substance abuse, and special populations such as children, the elderly and pregnant women Each section features a full reference list so the evidence base can be checked quickly and easily This title is also available as a mobile App from MedHand Mobile Libraries. Buy it now from iTunes, Google Play or the MedHand Store.

מידע נוסף

מידע נוסף
מהדורה	12
עמודים	760
מחליף את פריט	14597948000
פורמט	Paperback / softback
ISBN10	1118754603
יצא לאור ב	Hoboken
תאריך יציאה לאור	10 בינו׳ 2015
תוכן עניינים	Preface xi Acknowledgements xii Notes on using The Maudsley Prescribing Guidelines xiii List of abbreviations xv Chapter 1 Plasma level monitoring of psychotropic drugs 1 Interpreting sample results 2 Acting on clozapine plasma concentration results 11 Interpreting post-mortem blood concentrations 13 Chapter 2 Schizophrenia 15 Antipsychotic drugs 15 General introduction 15 General principles of prescribing 20 Minimum effective doses 22 Quick reference for licensed maximum doses 24 Equivalent doses 26 High-dose antipsychotics: prescribing and monitoring 28 Antipsychotic prophylaxis 31 Combined antipsychotics 37 Negative symptoms 41 Monitoring 45 Relative adverse effects a rough guide 48 Treatment algorithms for schizophrenia 49 First ]generation antipsychotics place in therapy 52 Omega-3 fatty acid (fish oils) in schizophrenia 54 New and developing drugs to treat schizophrenia 56 NICE guidelines for the treatment of schizophrenia 59 Antipsychotic response to increase the dose, to switch, to add or just wait what is the right move? 61 Antipsychotic long ]acting injections 66 Depot antipsychotics pharmacokinetics 70 Management of patients on long ]term depots 72 Aripiprazole LAI 74 Olanzapine LAI 75 Paliperidone palmitate LAI 77 Risperidone LAI 80 ANTIPSYCHOT ICS ADVERSE EFFECTS 84 Extrapyramidal side-effects 84 Akathisia 88 Weight gain 90 Treatment of drug-induced weight gain 92 Tardive dyskinesia 97 Neuroleptic malignant syndrome 102 Catatonia 105 QT prolongation 110 Dyslipidaemia 117 Diabetes and impaired glucose tolerance 121 Hypertension 128 Hyponatraemia 130 Hyperprolactinaemia 133 Sexual dysfunction 137 Pneumonia 143 Switching antipsychotics 144 REFRACTORY SCHIZOPHRENIA AND CLOZAPINE 147 Clozapine dosing regimen 147 Optimising clozapine treatment 149 Alternatives to clozapine 153 Restarting clozapine after a break in treatment 159 Initiation of clozapine for community-based patients 160 CLOZAPINE ADVERSE EFFECTS 165 Common adverse effects 165 Clozapine: uncommon or unusual adverse effects 168 Clozapine: serious haematological and cardiovascular adverse effects 170 Clozapine-induced hypersalivation 174 Clozapine-induced gastrointestinal hypomotility (CIGH) 177 Clozapine, neutropenia and lithium 181 Clozapine and chemotherapy 186 Chapter 3 Bipolar affective disorder 189 Lithium 189 Valproate 197 Carbamazepine 203 Antipsychotics in bipolar disorder 208 Treatment of acute mania or hypomania 211 Bipolar depression 216 Rapid-cycling bipolar affective disorder 223 Prophylaxis in bipolar affective disorder 225 Physical monitoring for people with bipolar affective disorder 228 Chapter 4 Depression and anxiety 231 Introduction 231 Basic principles of prescribing in depression 231 Official guidance on the treatment of depression 232 Antidepressants: general overview 233 St John s wort 246 Recognised minimum effective doses of antidepressants 250 Drug treatment of depression 252 Treatment of refractory depression 255 Psychotic depression 266 Electroconvulsive therapy and psychotropic drugs 269 Psychostimulants in depression 272 Post-stroke depression 276 Treatment of depression in the elderly 279 Antidepressant discontinuation symptoms 283 Antidepressant prophylaxis 287 Antidepressants: alternative routes of administration 290 Antidepressants: swapping and stopping 296 Drug interactions with antidepressants 303 Cardiac effects of antidepressants 307 Antidepressant-induced arrhythmia 312 Antidepressant-induced hyponatraemia 316 Antidepressants and hyperprolactinaemia 319 Antidepressants and diabetes mellitus 321 Antidepressants and sexual dysfunction 324 SSR Is and bleeding 328 Antidepressants: relative adverse effects a rough guide 332 Anxiety spectrum disorders 334 Benzodiazepines in the treatment of psychiatric disorders 343 Benzodiazepines: dependence and detoxification 346 Benzodiazepines and disinhibition 350 Chapter 5 Children and adolescents 353 Principles of prescribing practice in childhood and adolescence 353 Depression in children and adolescents 355 Bipolar illness in children and adolescents 362 Psychosis in children and adolescents 367 Anxiety disorders in children and adolescents 369 Obsessive compulsive disorder in children and adolescents 374 Post-traumatic stress disorder in children and adolescents 379 Attention deficit hyperactivity disorder 384 Autism spectrum disorders 390 Tics and Tourette s syndrome 397 Melatonin in the treatment of insomnia in children and adolescents 402 Rapid tranquillisation in children and adolescents 405 Doses of commonly used psychotropic drugs in children and adolescents 408 Chapter 6 Substance misuse 409 Introduction 409 Alcohol dependence 411 Opioid misuse and dependence 429 Nicotine and smoking cessation 456 Pharmacological treatment of dependence on stimulants 463 Benzodiazepine misuse 466 GBL and GHB dependence 467 Drugs of misuse: a summary 469 Interactions between street drugs and prescribed psychotropic drugs 472 Chapter 7 Use of psychotropic drugs in special patient groups 477 The elderly 477 Dementia 487 Safer prescribing of physical health medicines in dementia 507 Management of non-cognitive symptoms of dementia 517 Parkinson s disease 529 Multiple sclerosis 533 Huntington s disease 538 Pregnancy 541 Breastfeeding 559 Renal impairment 576 Hepatic impairment 590 HIV infection 598 Eating disorders 607 Acutely disturbed or violent behaviour 611 Borderline personality disorder 618 Learning disabilities 621 Delirium 625 Epilepsy 632 Surgery 637 Velo-cardio-facial syndrome 643 Cytochrome (CY P) function 646 Psychiatric side-effects of non-psychotropic drugs 650 Atrial fibrillation 656 Chapter 8 Miscellaneous conditions and substances 659 Psychotropic drugs in overdose 659 Biochemical and haematological effects of psychotropics 665 Prescribing drugs outside their licensed indications ( off-label prescribing) 673 Observations on the placebo effect in mental illness 676 Drug interactions with alcohol 679 Nicotine 684 Smoking and psychotropic drugs 688 Caffeine 690 Complementary therapies 695 Enhancing medication adherence 700 Driving and psychotropic medicines 706 Covert administration of medicines within food and drink 714 Index 717
זמן אספקה	21 ימי עסקים